Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats corneal cystine crystal accumulation. Sold as Cystaran, Cystadrops. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Cysteamine Hydrochloride (sold as Cystaran, Cystadrops), first approved Oct 2, 2012, with 0 new uses approved and 1 published complete response letter.
First approved: Oct 2, 2012
Applications: 2
New uses approved: 0
Complete response letters: 1
Medicare spending, 2025: $5.8M
First approved in Japan: Mar 26, 2024
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 138 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Cystadrops, new ingredientA drug with a new active ingredient indicated for the reduction of corneal cystine crystals in patients with cystinosis. · Viatris Pharmaceuticals Japan Inc. · Mar 26, 2024
Clinical Trials
7 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
